Browsing Tag
Shionogi
2 posts
GSK locks in ViiV Healthcare majority as Shionogi doubles down and Pfizer exits with $1.8bn
GSK retains 78.3% of ViiV Healthcare as Shionogi doubles its stake to 21.7% for $2.125 bn and Pfizer exits. Read the full strategic analysis.
April 1, 2026
ViiV Healthcare’s Cabenuva secures FDA approval for HIV treatment
ViiV Healthcare has received FDA approval for Cabenuva, a long-acting treatment regimen for HIV-1 infection in adult patients.…
January 24, 2021